

# Douglas S Goodin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5260296/publications.pdf>

Version: 2024-02-01

70  
papers

4,942  
citations

136950

32  
h-index

98798

67  
g-index

71  
all docs

71  
docs citations

71  
times ranked

5523  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 268-281.	5.3	39
2	Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive <sc>MS</sc>" <i>Annals of Neurology</i> , 2022, 91, 735-736.	5.3	0
3	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1432-1441.	3.0	9
4	The nature of genetic and environmental susceptibility to multiple sclerosis. <i>PLoS ONE</i> , 2021, 16, e0246157.	2.5	29
5	Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions. <i>BMC Medical Genomics</i> , 2021, 14, 183.	1.5	5
6	Genetic susceptibility to multiple sclerosis in African Americans. <i>PLoS ONE</i> , 2021, 16, e0254945.	2.5	5
7	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. <i>American Journal of Neuroradiology</i> , 2020, 41, 2219-2226.	2.4	14
8	Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. <i>Multiple Sclerosis Journal</i> , 2019, 25, 837-847.	3.0	23
9	Silent progression in disease activity-free relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2019, 85, 653-666.	5.3	265
10	Harnessing electronic medical records to advance research on multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 408-418.	3.0	21
11	Reply to Tsvigoulis and colleagues comments. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 120-121.	2.0	1
12	Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0190043.	2.5	20
13	Comparing the efficacy of disease-modifying therapies in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 109-116.	2.0	25
14	The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities. <i>BMC Neurology</i> , 2016, 16, 56.	1.8	13
15	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , 2016, 80, 499-510.	5.3	331
16	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1349-1358.	3.0	54
17	Relapses in multiple sclerosis: Relationship to disability. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 10-20.	2.0	36
18	Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies. <i>International Journal of MS Care</i> , 2015, 17, 74-82.	1.0	64

#	ARTICLE	IF	CITATIONS
19	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 897.	9.0	78
20	The pathogenesis of multiple sclerosis. Clinical and Experimental Neuroimmunology, 2015, 6, 2-22.	1.0	6
21	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology, 2015, 262, 2466-2471.	3.6	4
22	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurology, 2015, 72, 1458.	9.0	130
23	Haplotype-based approach to known MS-associated regions increases the amount of explained risk. Journal of Medical Genetics, 2015, 52, 587-594.	3.2	22
24	Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations. PLoS ONE, 2014, 9, e90034.	2.5	10
25	Glucocorticoid treatment of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 455-464.	1.8	47
26	Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. Journal of the Neurological Sciences, 2014, 344, 80-87.	0.6	64
27	The epidemiology of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 231-266.	1.8	136
28	Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 545-556.	10.2	707
29	Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States. PLoS ONE, 2014, 9, e105207.	2.5	34
30	Mortality in patients with multiple sclerosis. Neurology, 2013, 81, 184-192.	1.1	199
31	The Use of Interferon Beta and Glatiramer Acetate in Multiple Sclerosis. Seminars in Neurology, 2013, 33, 013-025.	1.4	9
32	Response to GS Gronseth and E Ashman. Multiple Sclerosis Journal, 2012, 18, 1661-1662.	3.0	2
33	Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Multiple Sclerosis Journal, 2012, 18, 181-195.	3.0	33
34	Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon $\beta$ -1b trial in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 282-287.	1.9	87
35	Cause of death in MS: long-term follow-up of a randomised cohort, 21...years after the start of the pivotal IFN $\beta$ -1b study. BMJ Open, 2012, 2, e001972.	1.9	37
36	Evidence-based medicine: promise and pitfalls. Multiple Sclerosis Journal, 2012, 18, 947-948.	3.0	7

#	ARTICLE	IF	CITATIONS
37	Treatment With Interferon Beta for Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2012, 308, 1627.	7.4	10
38	Variability in detection and quantification of interferon $\beta$ -1b-induced neutralizing antibodies. Journal of Neuroinflammation, 2012, 9, 129.	7.2	9
39	The Genetic and Environmental Bases of Complex Human-Disease: Extending the Utility of Twin-Studies. PLoS ONE, 2012, 7, e47875.	2.5	12
40	Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. PLoS ONE, 2011, 6, e22444.	2.5	34
41	The genetic basis of multiple sclerosis: a model for MS susceptibility. BMC Neurology, 2010, 10, 101.	1.8	19
42	Long-term follow-up of the original interferon- $\beta$ 1b trial in multiple sclerosis: Design and lessons from a 16-year observational study. Clinical Therapeutics, 2009, 31, 1724-1736.	2.5	35
43	250 $\mu$ g or 500 $\mu$ g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology, The, 2009, 8, 889-897.	10.2	377
44	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	2.9	419
45	The Causal Cascade to Multiple Sclerosis: A Model for MS Pathogenesis. PLoS ONE, 2009, 4, e4565.	2.5	192
46	The impact of warâ€stress on MS exacerbations. Annals of Neurology, 2008, 64, 114-115.	5.3	4
47	Disease-modifying therapy in multiple sclerosis. Neurology, 2008, 71, S8-13.	1.1	71
48	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Current Medical Research and Opinion, 2007, 23, 2823-2832.	1.9	7
49	Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?. Annals of Neurology, 2006, 59, 597-605.	5.3	103
50	Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept. Brain, 2006, 129, e56-e56.	7.6	0
51	Marijuana and multiple sclerosis. Lancet Neurology, The, 2004, 3, 79-80.	10.2	12
52	Disease-modifying therapy in MS: a critical review of the literature. Journal of Neurology, 2004, 251, v3-v11.	3.6	11
53	Disease-modifying therapy in MS: a critical review of the literature. Journal of Neurology, 2004, 251, v50-v56.	3.6	11
54	Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans. American Journal of Human Genetics, 2004, 74, 160-167.	6.2	311

#	ARTICLE	IF	CITATIONS
55	RELATIONSHIP BETWEEN MULTIPLE SCLEROSIS EXACERBATIONS AND STRESS: RESPONSE. Psychosomatic Medicine, 2004, 66, 288-289.	2.0	3
56	Interferon-?? Therapy in Multiple Sclerosis. Drugs, 2001, 61, 1693-1703.	10.9	23
57	Studies of the human stretch reflex. Muscle and Nerve, 2000, 23, S3-S6.	2.2	5
58	Therapeutic developments in multiple sclerosis. Expert Opinion on Investigational Drugs, 2000, 9, 655-670.	4.1	12
59	Order effects in response times of parkinsonian patients and normal controls. , 1999, 22, 567-572.		3
60	Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch in patients with Huntington's disease. Muscle and Nerve, 1999, 22, 1557-1563.	2.2	8
61	Perils and Pitfalls in the Interpretation of Clinical Trials: A Reflection on the Recent Experience in Multiple Sclerosis. Neuroepidemiology, 1999, 18, 53-63.	2.3	45
62	A questionnaire to assess neurological impairment in multiple sclerosis. Multiple Sclerosis Journal, 1998, 4, 444-451.	3.0	49
63	Nonrandom behavior in a reaction-time time series. Muscle and Nerve, 1996, 19, 1183-1185.	2.2	2
64	A comparison of magnetic and electrical stimulation of peripheral nerves. Muscle and Nerve, 1990, 13, 957-963.	2.2	84
65	Effects of different sensory inputs on the median-derived somatosensory evoked potential. Muscle and Nerve, 1989, 12, 598-603.	2.2	12
66	Magnetic resonance imaging in amyotrophic lateral sclerosis. Annals of Neurology, 1988, 23, 418-420.	5.3	137
67	Electrophysiological differences between demented and nondemented patients with Parkinson's disease. Annals of Neurology, 1987, 21, 90-94.	5.3	153
68	Subclasses of event-related potentials: Response-locked and stimulus-locked components. Annals of Neurology, 1986, 20, 603-609.	5.3	22
69	Dermatomal somatosensory evoked potentials unilateral lumbosacral radiculopathy. Annals of Neurology, 1985, 17, 171-176.	5.3	94
70	An Early Event-Related Cortical Potential. Psychophysiology, 1978, 15, 360-365.	2.4	87